Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

As a foundation of care in SMA, more than 14,000 individuals have been treated with SPINRAZA worldwide.1 The currently approved 12 mg regimen for SPINRAZA is comprised of four loading doses ...

Spinraza plays a vital role in SMA treatment by: .Boosting SMN protein levels through spinal injection. .Improving motor function and slowing disease progression. According to the National Library ...

In 2016, Spinraza became the first approved treatment for SMA, with exceptional results in infants with severe SMA – so exceptional, it was considered unethical to continue enrolling children ...

Nusinersen is currently commercialized under the brand name SPINRAZA in over 71 countries at the label-approved dose of 12 mg. "Continued progress to improve upon the remarkable initial successes in ...